STOCK TITAN
  1. Home
  2. Sec-filings
  3. NKTR
  4. [144] NEKTAR THERAPEUTICS SEC Filing

Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS (NKTR) had a Form 144 notice filed in connection with planned sales of its common stock by officer Jonathan Zalevsky. The notice covers a proposed sale of 186 shares of NKTR common stock, with an aggregate market value of $13,387.96 as of August 18, 2026, to be sold on NASDAQ. The securities to be sold were acquired through restricted stock vesting on August 14, 2026, as compensation from the issuer. The filer also reports that the planned sale includes shares needed to cover a related tax obligation, and notes a prior sale of 199 shares for $13,035.36 on May 19, 2026.

Positive

  • None.

Negative

  • None.
Shares planned for sale 186 shares Common stock covered by the Form 144 notice
Aggregate market value of planned sale $13,387.96 Value for 186 NKTR shares as of August 18, 2026
Security identifier 34142994 Numeric identifier listed with the common stock entry
Prior shares sold 199 shares Common stock sold on May 19, 2026
Aggregate amount of prior sale $13,035.36 Total for 199 NKTR shares sold on May 19, 2026
Date of notice 08/18/2026 Date the Form 144 notice was signed and filed
Acquisition date of vested stock 08/14/2026 Date of restricted stock vesting underlying the planned sale
Form 144 regulatory
"144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"Common | 08/14/2026 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
vested equity award financial
"resulting from the settlement of a vested equity award distribution."

FAQ

What does the Form 144 filing mean for NEKTAR THERAPEUTICS (NKTR)?
The Form 144 for NEKTAR THERAPEUTICS (NKTR) discloses an officer’s planned sale of 186 shares of common stock. It is a regulatory notice for potential sales under Rule 144, not a company-level financing transaction.

How many NKTR shares are covered by Jonathan Zalevsky’s planned sale?
The notice covers a planned sale of 186 shares of NEKTAR THERAPEUTICS common stock. These shares relate to restricted stock vesting on August 14, 2026, and part of the sale is intended to cover associated tax obligations.

What is the reported value of the NKTR shares in the new Form 144?
The Form 144 lists an aggregate market value of $13,387.96 for the 186 shares of NKTR common stock. This value is tied to the planned sale on NASDAQ as of the notice date of August 18, 2026.

What prior NKTR stock sales by Jonathan Zalevsky are disclosed?
The filing reports that on May 19, 2026, Jonathan Zalevsky sold 199 shares of NEKTAR THERAPEUTICS common stock for an aggregate amount of $13,035.36. This transaction occurred within the three months preceding the new Form 144 notice.

How were the NKTR shares to be sold originally acquired by Jonathan Zalevsky?
The shares were acquired through restricted stock vesting on August 14, 2026 as compensation from NEKTAR THERAPEUTICS. The Form 144 notes the transaction type as “Restricted Stock Vesting” with the nature of acquisition described as Compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR